JP2005535687A5 - - Google Patents

Download PDF

Info

Publication number
JP2005535687A5
JP2005535687A5 JP2004525349A JP2004525349A JP2005535687A5 JP 2005535687 A5 JP2005535687 A5 JP 2005535687A5 JP 2004525349 A JP2004525349 A JP 2004525349A JP 2004525349 A JP2004525349 A JP 2004525349A JP 2005535687 A5 JP2005535687 A5 JP 2005535687A5
Authority
JP
Japan
Prior art keywords
tds
phase
rotigotine
hydrophilic
emulsify
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004525349A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005535687A (ja
JP4837916B2 (ja
Filing date
Publication date
Priority claimed from EP02016860A external-priority patent/EP1386605A1/en
Application filed filed Critical
Publication of JP2005535687A publication Critical patent/JP2005535687A/ja
Publication of JP2005535687A5 publication Critical patent/JP2005535687A5/ja
Application granted granted Critical
Publication of JP4837916B2 publication Critical patent/JP4837916B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2004525349A 2002-07-30 2003-07-28 ロチゴチン投与のための改善された経皮送達系 Expired - Lifetime JP4837916B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02016860A EP1386605A1 (en) 2002-07-30 2002-07-30 Improved transdermal delivery system for the administration of rotigotine
EP02016860.5 2002-07-30
PCT/EP2003/008320 WO2004012730A1 (en) 2002-07-30 2003-07-28 Improved transdermal delivery system for the administration of rotigotine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011133638A Division JP5564469B2 (ja) 2002-07-30 2011-06-15 ロチゴチン投与のための改善された経皮送達系

Publications (3)

Publication Number Publication Date
JP2005535687A JP2005535687A (ja) 2005-11-24
JP2005535687A5 true JP2005535687A5 (cg-RX-API-DMAC7.html) 2006-06-08
JP4837916B2 JP4837916B2 (ja) 2011-12-14

Family

ID=30011090

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004525349A Expired - Lifetime JP4837916B2 (ja) 2002-07-30 2003-07-28 ロチゴチン投与のための改善された経皮送達系
JP2011133638A Expired - Lifetime JP5564469B2 (ja) 2002-07-30 2011-06-15 ロチゴチン投与のための改善された経皮送達系

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011133638A Expired - Lifetime JP5564469B2 (ja) 2002-07-30 2011-06-15 ロチゴチン投与のための改善された経皮送達系

Country Status (19)

Country Link
EP (2) EP1386605A1 (cg-RX-API-DMAC7.html)
JP (2) JP4837916B2 (cg-RX-API-DMAC7.html)
KR (1) KR101016838B1 (cg-RX-API-DMAC7.html)
CN (2) CN1671375A (cg-RX-API-DMAC7.html)
AT (1) ATE322263T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003258539B2 (cg-RX-API-DMAC7.html)
BR (1) BR0313091A (cg-RX-API-DMAC7.html)
CA (1) CA2491366A1 (cg-RX-API-DMAC7.html)
DE (1) DE60304477T2 (cg-RX-API-DMAC7.html)
DK (1) DK1524975T3 (cg-RX-API-DMAC7.html)
ES (1) ES2256780T3 (cg-RX-API-DMAC7.html)
IL (1) IL165918A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA05000350A (cg-RX-API-DMAC7.html)
NO (1) NO333297B1 (cg-RX-API-DMAC7.html)
PL (1) PL217079B1 (cg-RX-API-DMAC7.html)
PT (1) PT1524975E (cg-RX-API-DMAC7.html)
SI (1) SI1524975T1 (cg-RX-API-DMAC7.html)
WO (1) WO2004012730A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200500252B (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
EP1386604A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE10361259A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
EP1796610A4 (en) * 2004-09-29 2012-12-05 Schwarz Pharma Inc TRANSDERMAL THERAPEUTIC SYSTEM FOR PARKINSON'S DISEASE
US7353034B2 (en) 2005-04-04 2008-04-01 X One, Inc. Location sharing and tracking using mobile phones or other wireless devices
CA2739380C (en) * 2008-10-06 2014-12-09 Mylan Technologies, Inc. Amorphous rotigotine transdermal system
DE102008060203A1 (de) 2008-12-07 2010-06-10 Dietrich Wilhelm Schacht Wirkstoffstabilisierende flächenförmige Vorrichtung
EP2201941A1 (de) 2008-12-29 2010-06-30 UCB Pharma GmbH Pflaster-Herstellungstechnologie
WO2011076879A1 (en) * 2009-12-22 2011-06-30 Ucb Pharma Gmbh Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
JP5820469B2 (ja) 2010-04-30 2015-11-24 テイコク ファーマ ユーエスエー インコーポレーテッド プロピニルアミノインダンの経皮組成物
EP2688561B1 (en) 2011-03-24 2018-08-22 Teikoku Pharma USA, Inc. Transdermal compositions comprising an active agent layer and an active agent conversion layer
EP2559435A1 (en) 2011-08-19 2013-02-20 UCB Pharma GmbH Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
EP2776020B1 (en) 2011-11-09 2019-09-11 Teikoku Seiyaku Co., Ltd. Methods for the treatment of skin neoplasms
DE102011119043A1 (de) 2011-11-22 2013-05-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TDS) mit Rotigotin
DE102011090178A1 (de) 2011-12-30 2013-07-04 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
KR101558042B1 (ko) * 2012-07-05 2015-10-07 에스케이케미칼주식회사 로티고틴을 함유한 경피흡수제제
JP6050896B2 (ja) 2012-11-02 2016-12-21 テイコク ファーマ ユーエスエー インコーポレーテッド プロピニルアミノインダン経皮組成物
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀(Rotigotine)之多天式貼片
JP2016135744A (ja) * 2013-05-08 2016-07-28 株式会社 ケイ・エム トランスダーム 貼付剤
WO2014198423A1 (de) 2013-06-14 2014-12-18 Tesa Labtec Gmbh Dreischichtiges transdermales therapiesystem (tts)
WO2014198422A1 (de) 2013-06-14 2014-12-18 Tesa Labtec Gmbh Transdermales therapiesystem (tts) mit rotigotin
CN105358139B (zh) 2013-07-03 2020-10-16 Lts罗曼治疗方法有限公司 具有电子元件的经皮治疗系统
ES2954087T3 (es) 2014-05-20 2023-11-20 Lts Lohmann Therapie Systeme Ag Sistema de administración transdérmica que incluye un mediador de interfase
CN106456567A (zh) * 2014-05-20 2017-02-22 Lts勒曼治疗系统股份公司 在经皮递送系统中调节活性剂释放的方法
JP6573913B2 (ja) * 2014-05-20 2019-09-11 エルテーエス ローマン テラピー−ジステーメ アーゲー ロチゴチンを含む経皮送達システム
KR102364378B1 (ko) 2014-05-21 2022-02-16 에스케이케미칼 주식회사 안정성을 향상시킨 로티고틴 함유 경피흡수제제
CN104382850B (zh) * 2014-10-17 2017-12-22 烟台大学 一种罗替戈汀微乳及微乳凝胶
WO2019234662A1 (en) * 2018-06-07 2019-12-12 Nal Pharmaceutical Group Limited Transdermal drug delivery system containing rotigotine
DK3854388T3 (da) 2020-01-24 2023-11-27 Luye Pharma Switzerland Ag Transdermalt terapeutisk system omfattende rotigotin og mindst et ikke-aminresistent silikoneklæbestof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989586A (en) * 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19814083C2 (de) * 1998-03-30 2002-02-07 Lohmann Therapie Syst Lts Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen
DE19940238A1 (de) * 1999-08-25 2001-03-01 Lohmann Therapie Syst Lts Wirkstoffhaltiges therapeutisches System zur Applikation auf der Haut mit mindestens zwei polymerhaltigen Schichten
PT1256340E (pt) * 2001-05-08 2003-12-31 Sanol Arznei Schwarz Gmbh Sistema terapeutico transdermico aperfeicoado para o tratamento da doenca de parkinson
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
EP1386604A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system

Similar Documents

Publication Publication Date Title
KR101016838B1 (ko) 로티고틴 투여를 위한 향상된 경피 송달 시스템
TWI435737B (zh) 經皮遞送醫藥化合物的方法及其組成物
US8617591B2 (en) Transdermal delivery system for the administration of rotigotine
JP2005535686A5 (cg-RX-API-DMAC7.html)
JP5069402B2 (ja) フェンタニル懸濁液をベースにしたシリコーン系粘着剤製剤及びフェンタニルを経皮送達するための装置
US8246980B2 (en) Transdermal delivery system
JP6132407B2 (ja) ドネペジルを含有する経皮吸収製剤及びその製造方法
JP2015083569A (ja) 安定化された経皮薬物送達システム
CN102548546A (zh) 用于施用芬太尼或其类似物的透皮治疗系统
JP2008507495A (ja) 活性本体の経皮送達用デバイス
KR101016914B1 (ko) 향상된 경피 송달 시스템
Hadgraft et al. Passive transdermal drug delivery systems: recent considerations and advances
KR20050099537A (ko) 활성 물질의 투과를 촉진시키기 위한 가열 용도에 적합한경피 치료 시스템, 및 이의 용도
KR20160106181A (ko) 피부 투과 촉진 조성물, 경피 투여 제제 및 첩부 제제
Shokri et al. The effect of pore-formers and plasticizers on the release kinetic of diltiazem hydrochloride from the controlled porosity osmotic pumps
KR20200046461A (ko) 비결정 로티고틴 함유 조성물 및 이의 제조 방법
HK1083458B (en) Improved transdermal delivery system
HK1062650A (en) Improved transdermal delivery system for the administration of rotigotine